On this page
Hyaluronidase (HUMAN RECOMBINANT)
Active ingredient 11 prescription 15 with labelling
Overview
Source: NDC DirectoryIngredient name
HYALURONIDASE (HUMAN RECOMBINANT)
Base moiety
HYALURONIDASE (HUMAN RECOMBINANT)
RxNorm CUI
UNII
743QUY4VD8
Medication products
12
Brand names
11
Dosage forms
2
FAERS reports
220,213 · not a risk measure
- Darzalex Faspro daratumumab and hyaluronidase-fihj (human recombinant) · Injection
- Herceptin Hylecta Trastuzumab and hyaluronidase-oysk · Injection, Solution
- HYALURONIDASE Hyaluronidase · Injection, Solution
- HYLENEX Recombinant Hyaluronidase · Injection, Solution
- Ocrevus Zunovo ocrelizumab and hyaluronidase · Injection, Solution
- rHuPH20 Injection
- Tecentriq Hybreza atezolizumab and hyaluronidase-tqjs · Injection
- OPDIVO QVANTIG nivolumab and hyaluronidase-nvhy · Injection, Solution
- Phesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf · Injection, Solution
- Rituxan Hycela rituximab and hyaluronidase · Injection, Solution
- Rybrevant Faspro AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) · Injection
- VYVGART Hytrulo efgartigimod alfa and hyaluronidase (human recombinant) · Injection, Solution
Entries without a link are products listed by the FDA that carry no approval record, therapeutic equivalence rating or official labelling, so they have no detail page. Their facts are shown inline.
By dosage form
| Dosage form | Products | Examples |
|---|---|---|
| INJECTION, Solution | 8 | Herceptin Hylecta, HYALURONIDASE, HYLENEX Recombinant, Ocrevus Zunovo … |
| Injection | 4 | Darzalex Faspro, rHuPH20, Tecentriq Hybreza, Rybrevant Faspro |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Ingredient name, strengths, products, labelers, packages |
| DailyMed RxNorm mappings | NLM | RxNorm concept identifier (RxCUI) |
| FAERS | FDA | Adverse event report totals |